Michael J. Fox Foundation for Parkinson's Research

2016 · research · Target Advancement Program

Biochemical Analysis and Structural Determination of LRRK2 with Kinase Inhibitors

Hao Wu · Boston Children's Hospital

2016 · research · Research Grant

MJFF Recruitment Centers of Excellence

Holly Shill · Barrow Neurological Institute

2016 · research · Target Advancement Program

Structural Insights into Activated Intermediates of Parkin

Kalle Gehring · McGill University

2016 · research · Research Grant

Clinicopathological Features of LRRK2-related Parkinson's Disease

Lorraine V. Kalia · University of Toronto

2016 · research · Biomarkers Across Neurodegenerative Diseases

Cross-disease Brain Image Modeling

Yuanfang Guan · University of Michigan

2016 · research · Target Advancement Program

Imaging Endogenous LRRK2 Cells

Nicolas Dzamko · The University of Sydney

2016 · research · Research Grant

Identification of Slow Off-rate Modified Aptamer Reagents that Specifically Bind Phosphorylated LRRK2

Amy D. Gelinas · Somalogic, Inc.

2016 · research · Target Advancement Program

Targeting RER1 in Models of Parkinson's Disease

Nikolaus Mcfarland · University of Florida

2016 · research · Therapeutic Pipeline Program

Small Molecule Inhibitors of C-Abl for Parkinson's Disease Modification

Milton H. Werner · Inhibikase Therapeutics, Inc.

2016 · research · Research Grant

Further Validation of SIRT3 in a Parkinsonian Model

Laura Volpicelli-Daley · UAB Medicine

2016 · research · Target Advancement Program

Validation of a Protein, Transglutaminase 2, as a Way to Reduce Alpha-synuclein Clumping and Toxicity in Parkinson's Disease

Mary Maral Mouradian · William Dow Lovett Professor Of Neurology; Director Of The Rwjms Institute For Neurological Therapeutics; And Vice Chancellor For Faculty Development, Rutgers Biomedical And Health Sciences - Robert Wood Johnson Medical School

2016 · research · Research Grant

Study of Alpha-synuclein in the Dorsal Neostriatum

Sylvie Ramboz · Psychogenics (United States)

2016 · research · Target Advancement Program

Role of PINK1 and Parkin in Innate Immunity: Crosstalk between Mitochondrial Dysfunction and NLRP3 Inflammasome Signaling

Olga Corti · Brain And Spine Institute (institut Du Cerveau Et De La Moelle épinière)

2016 · research · Target Advancement Program

Investigating the Effect of Parkin on Alpha-synuclein Propagation

Thomas M. Durcan · McGill University

2016 · research · Therapeutic Pipeline Program

Novel LRRK2 Antisense Oligonucleotides as a Therapy for Parkinson's Disease

Michelle L. Hastings · Rosalind Franklin University of Medicine and Science

2016 · research · Research Grant

Antibody Development for Modified Parkin Proteins Identified in the Human Brain

Peggy Taylor · Biolegend, Inc.

2016 · research · Research Grant

Multi-center Study of EEG Biomarkers for Alpha-synucleinopathy Diagnosis and Prognosis Decision Support Tools Using Machine Learning

Giulio Ruffini · Starlab Barcelona SLU (Spain)

2016 · research · Research Grant

Identification of Epigenetic Signatures in Blood as Biomarkers for Parkinson's Disease

2016 · research · Research Grant

Electrical Stimulation of the Brain as Parkinson's Disease Treatment

Coralie De Hemptinne · University of California, San Francisco

2016 · research · Target Advancement Program

Mechanism of TFEB Dysfunction by GBA1 Mutation in Human iPSC-derived Dopaminergic Neurons

Ola A. Awad · University of Maryland, College Park

2016 · research · LRRK2 Therapeutic and Safety Initiative

Evaluation of LRRK2 Inhibition in a Pre-clinical Model of Parkinson's Disease

James B. Koprich · Atuka, Inc.

2016 · research · Research Grant

Rab Detection Initiative and LRRK2 Detection Initiative Supplemental Support RDI, and LCC exosome replication

Marie-Christine Chartier-Harlin · Umr-s1172, Jean-pierre Aubert Research Center (inserm - Lille University - Lille University Hospital

2016 · research · PPMI Data Challenge

Subtyping Parkinson’s Disease with Deep Learning Models (2016 PPMI Data Challenge Winner)

Fei Wang · Weill Cornell Medicine

2016 · research · Biomarkers Across Neurodegenerative Diseases

Network Models of Neurodegeneration (NetMON)

Neil P. Oxtoby · University College London

2016 · research · Research Grant

Characterization, Optimization and Validation of a Preformed Fibril Pre-clinical Model of Parkinson's Disease

James B. Koprich · Atuka, Inc.

2016 · research · Research Grant

Convergence of LRRK2 and GBA1 in the Pathogenesis of Parkinson's Disease

Dimitri Krainc · Northwestern University

2016 · research · Research Grant

LRRK2 Safety Initiative

Stephen A. Ploch · Covance Laboratories, Inc.

2016 · research · Target Advancement Program

Targeting the LRRK2-PAK6 Pathway in Parkinson's Disease

Laura Cendron · University of Padua

2016 · research · Research Grant

Optimization of Nigrostriatal Degeneration in the Alpha-synuclein Preformed Fibril Model

Caryl E. Sortwell · Michigan State University

2016 · research · Research Grant

Evaluation of LRRK2 Kinase Activity in Blood Cells

Thomas Gasser · Hertie Institute for Clinical Brain Research

2016 · research · Target Advancement Program

Studying Monocyte Entry into the Brain in Alpha-synuclein-induced Parkinson's Disease

Ashley S. Harms · University of Alabama at Birmingham

2016 · research · PPMI Data Challenge

Multivariate Prediction of Parkinson's Disease Clinical Progression (2016 PPMI Data Challenge Winner)

Duygu Tosun-Turgut · University of California, San Francisco

2016 · research · Therapeutic Pipeline Program

Structure Window into LRRK2: Kinase or Pseudokinase?

Susan S. Taylor · University of California San Diego

2016 · research · Research Grant

Structural Studies on LRRK2 Kinase Using X-Ray Crystallography

Stefan Knapp · Frankfurt University

2016 · research · Therapeutic Pipeline Program

Small-molecule Inhibitor to Stop Alpha-synuclein Spread for the Treatment of Parkinson's Disease

Edward A. Fon · McGill University